2023-10-20FDA expands pediatric indication for entrectinib and approves new pellet formulationTrial STARTRK-NGDrug Rozlytrek (entrectinib) · TRK inhibitor
2019-08-15FDA approves entrectinib for NTRK solid tumors and ROS-1 NSCLCTrials STARTRK-2, STARTRK-1Drug ROZLYTREK (entrectinib) · TRK inhibitorConditionsOther solid neoplasmThoracic
2018-11-26FDA approves larotrectinib for solid tumors with NTRK gene fusionsTrials SCOUT, NAVIGATEDrug VITRAKVI (larotrectinib) · TRK inhibitorConditionOther solid neoplasm